Harvard Bioscience
HBIO
79 hedge funds and large institutions have $74M invested in Harvard Bioscience in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 31 reducing their positions, and 19 closing their positions.
0.25% less ownership
Funds ownership: 7.19% → 6.94% (-0.25%)
12% less funds holding
Funds holding: 90 → 79 (-11)
26% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 31
31% less capital invested
Capital invested by funds: $107M → $74M (-$32.8M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
58% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$1.38M |
| 2 |
AE
AMH Equity
Great Neck,
New York
|
+$1.23M |
| 3 |
ACM
Archon Capital Management
Seattle,
Washington
|
+$1.15M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$870K |
| 5 |
2C
272 Capital
Dallas,
Texas
|
+$564K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$3.67M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$1.4M |
| 3 |
Millennium Management
New York
|
-$613K |
| 4 |
Renaissance Technologies
New York
|
-$496K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$448K |
HBIO Hedge Fund Activity: Q3 2022 in Review
79 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q3 2022, worth a combined $74M — down 31% from $107M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of HBIO and 8 opened new positions — a net loss of 11 holders — while 31 trimmed existing stakes and 23 added.
The largest buyer was Heartland Advisors, adding an estimated $1.38M. The largest seller was Portolan Capital Management, cutting an estimated $3.67M.
- 79 institutional investors held Harvard Bioscience (HBIO) as of Q3 2022, down from 90 in Q2 2022.
- Funds reported $74M of Harvard Bioscience stock for Q3 2022, down 31% quarter-over-quarter.
- 8 funds opened new Harvard Bioscience positions in Q3 2022 and 19 closed out, a net change of -11 holders.
- The largest Harvard Bioscience buyer in Q3 2022 was Heartland Advisors, an estimated $1.38M added.
- The largest Harvard Bioscience seller in Q3 2022 was Portolan Capital Management, an estimated $3.67M sold.
Based on aggregated 13F filings for Q3 2022.